Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 576 - 600 of 10466 in total

Glimepiride

First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Description: … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in …
Matched Categories: … Cardiovascular Agents ... Immunosuppressive Agents ... Blood Glucose Lowering Agents ... Hypoglycemia-Associated Agents …

Maralixibat

Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Description: … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor ... [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] ... [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients …

Nintedanib

Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … [L8453,L8459] It was first approved for use in the United States in 2014. …
Matched Categories: … Antifibrotic Agents ... Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Human papillomavirus type 11 L1 capsid protein antigen

Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus...
Approved
Matched Description: … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused …

Human papillomavirus type 58 L1 capsid protein antigen

Human papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. The vaccine is prepared from the purified...
Approved
Matched Description: … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused …

Betamethasone phosphate

Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention. Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.
Approved
Vet approved

Verapamil

Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs...
Approved
Matched Categories: … Antiarrhythmic agents ... Cardiovascular Agents ... Antihypertensive Agents ... Hypotensive Agents ... Vasodilating Agents …

Flurbiprofen

Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis....
Approved
Investigational
Matched Categories: … Nephrotoxic agents ... Antirheumatic Agents ... Agents causing hyperkalemia ... Anti-Inflammatory Agents ... Sensory System Agents …

Bisacodyl

Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and picosulfate are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952.
Approved
Matched Categories: … Gastrointestinal Agents …

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Description: … [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous ... Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes ... [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for …

Alginic acid

Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (Phacophycae) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscous gel when binding with water. Alginic acid is a linear polymer consisted...
Approved
Investigational
Matched Description: … Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and …

Glycerol phenylbutyrate

Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Matched Description: … FDA approved on February 1, 2013. …
Matched Categories: … Urea Cycle Disorder Agents …

Plecanatide

Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Description: … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation …
Matched Categories: … Gastrointestinal Agents …

Methylphenobarbital

A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
Approved
Matched Categories: … GABA Agents ... Anticholinergic Agents ... Neurotransmitter Agents ... Central Nervous System Agents …

Iron sucrose

Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron...
Approved
Matched Categories: … Phosphate-removing Agents …

Sodium lauryl sulfoacetate

Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.
Approved
Experimental

Technetium Tc-99m exametazime

Technetium Tc-99m exametazime is a radiopharmaceutical sold under the trade name Ceretec used in the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. Exametazime, also known as hexamethylpropyleneamine...
Approved

Polyethylene glycol 400

Polyethylene glycols (PEGs) are products made of condensed ethylene oxide and water that can contain various derivatives and have various functions. Because many PEG types are hydrophilic, they are favorably used as enhancers of penetration, and used heavily in topical dermatological preparations. PEGs, along with their many nonionic derivatives, are...
Approved
Matched Description: … nonionic derivatives, are widely utilized in cosmetic products as surfactants, emulsifiers, cleansing agents …
Matched Categories: … Pegylated agents …

Emtricitabine

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of...
Approved
Investigational
Matched Categories: … Anti-HIV Agents ... Antiviral Agents ... Anti-Infective Agents ... Anti-Retroviral Agents …

Alogliptin

Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Approved
Matched Description: … FDA approved January 25, 2013. …
Matched Categories: … Agents causing angioedema ... Blood Glucose Lowering Agents …

Relugolix

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment ... [L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and …
Matched Categories: … QTc Prolonging Agents ... Potential QTc-Prolonging Agents ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …

Lovastatin

Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid...
Approved
Investigational
Matched Description: … Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an ... result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while lovastatin has been found to have an …
Matched Categories: … Anticholesteremic Agents ... Hypolipidemic Agents ... Agents Causing Muscle Toxicity ... Lipid Modifying Agents ... Lipid Regulating Agents …

Vildagliptin

Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl ... [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment …
Matched Categories: … Agents causing angioedema ... Blood Glucose Lowering Agents …

Bacillus calmette-guerin substrain connaught live antigen

Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis....
Approved
Investigational

CVac

Approved
Investigational
Displaying drugs 576 - 600 of 10466 in total